Key facts
- Trince’s last known valuation is $19.9M (Dec 2025).
- It has raised $13.7M; the latest was Early Stage VC ($6.0M) in Dec 2025.
- Notable investors include Ghent University, Novalis Biotech, Qbic Fund.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Trince
- ·The full record, as it builds
Funding rounds
No funding rounds for Trince are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Trince
Developer of cell transfection technology designed to facilitate the delivery of molecules into cells both in vitro and ex vivo. The company's platform combines laser exposure with photothermal nanoparticles to convert light energy into heat to transiently permeabilize the cellular plasma membrane, enabling the healthcare industry to bring genetic material into cells in high throughput.
- Sector
- Healthcare
- HQ
- Ghent, Belgium
- Founded
- 2021
- Employees
- 16
- Website
- trincebio.com/
- Ownership
- Privately Held (backing)
Trince doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trince shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trince in its N-PORT filings yet. We sweep new filings monthly.